A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of ASP7035 in Patients with Nocturia Associated with Norturnal Polyuria
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
Price : $35 *
At a glance
- Drugs ASP 7035 (Primary)
- Indications Nocturia
- Focus Proof of concept; Therapeutic Use
- Sponsors Tacurion Pharma
- 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 26 Jul 2014 Status changed from planning to recruiting, as per European Clinical Trials Database record.
- 14 May 2013 New trial record